The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

The application was based on results from the three-arm Phase 3 CheckMate -8HW study.

A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially ...

Squibb announced the final analysis of overall survival, or OS, from the Phase 3 CheckMate -816 study, which evaluated ...

Of these 36 were given combination checkpoint inhibitor immunotherapy (anti-PD-1 plus anti-CTLA-4) and 43 were prescribed ...

(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...

Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

Pancreatic cancer is fueled by connections to the nervous system. This is reported by scientists from the German Cancer ...